Operating cash swung NZ$18.9m negative as revenue fell 19.2%

Net cash flow from operating activities swung from a $17.5m inflow in HY21 to a $1.4m outflow in HY22, an $18.9m deterioration, while reported NPAT of $1.0m remained positive. Cash on the balance sheet fell to $18.5m from $26.3m.

Revenue declined 19.2% to $48.7m, which management attributes to COVID-19 disruption and supply-chain constraints. PBT fell 70.5% to $1.3m and NPAT fell 76.7% to $4.3m → $1.0m. The 6.2 percentage-point gap between PBT and NPAT growth reflects a tax distortion: HY21 carried an effective tax rate of -3.3% (a credit), versus 22.5% in HY22, so PBT is the cleaner operating read.

Trade debtors rose 45.9% to $12.2m and receivable days lengthened from 25.3 to 45.7. Inventories fell 11.2% in dollar terms but inventory days rose to 78.6 from 71.5 as sales decelerated faster than stock. The group remains debt-free.

OCF/EBITDA ran at -55.2% in HY22 and FCF (pre-lease) of -$3.0m compares with +$16.4m a year earlier; FCF/NPAT was -296.3%. Reported profitability therefore tells you very little about the cash the business actually generated this half, which matters because Bremworth funded operations and a 43.8% lift in capex by drawing down its cash balance rather than by trading.

Working capital absorbed the cash. Receivable days nearly doubled (+20.4 days) and inventory days extended by 7.1 days. Operating working capital rose $1.2m on lower sales — a deterioration in efficiency, not absolute build-up. Until debtors normalise, reported earnings will continue to overstate cash generation.

Underlying operating profitability halved before tax effects. Stripping out the tax-rate swing, PBT fell 70.5% on a 19.2% revenue decline, implying material operating deleverage on a smaller revenue base. ROE dropped to 2.7% from 11.2%. This is the underlying read that the headline NPAT line, distorted by the prior-year tax credit, partly obscures.

The HY21 comparable was itself unusually strong: HY21 NPAT of $4.3m exceeded full-year FY21 NPAT of $1.7m, and HY21 operating cash flow was 108% of the FY21 total. The prior half therefore likely flatters the year-on-year decline.

That said, what the release does not support is any specific read on H2 FY22 recovery: there is no order-book disclosure, no margin guidance, and no commentary quantifying when supply-chain and COVID drags ease. The gap matters because cash will only rebuild if debtors are collected and revenue stabilises.

The $1.0m NPAT is supported by a near $19m unfavourable swing in operating cash flow, with the receivables blowout the largest single contributor. Capex stepped up to $1.6m (3.3% of revenue), with management noting over 50% was directed at manufacturing plant improvements — this is investment-led rather than maintenance-driven, but it sharpens the near-term cash drain.

Two structural positives soften the read. First, the balance sheet remains debt-free, so the cash outflow is funded from a $18.5m cash buffer rather than borrowings. Second, the tax line is the larger driver of the NPAT/PBT divergence; the underlying operating decline, while sharp, is not as severe as the -76.7% NPAT figure suggests. Even so, with FCF at -$3.0m and dividends at zero, capital return is appropriately suspended until cash conversion normalises.

This briefing cannot assess segment-level margins, order-book backlog, or H2 trading trajectory because none of those were disclosed in the supplied release.